Event Details
Agenda
Event Details
Meeting Summary
Meeting Objectives
ApoL1 susceptibility alleles, which are found primarily in African-Americans, are arguably the most important discovery about the pathogenesis of Chronic Kidney Disease over the past 5 years, and among the only known genetic factors contributing to the well-appreciated health disparities in kidney diseases. These variants may explain 70 percent of the excess focal segmental glomerulosclerosis, HIV-associated nephropathy, and hypertensive kidney disease in African Americans.
This conference/workshop will attempt to develop new ideas regarding and pathways to determining how risk alleles lead to disease susceptibility, what kidney and cardiovascular outcomes are associated with these variants, which additional genetic variants or multi-level environmental factors play a role in phenotypic differences, and the possible roles of ApoL1 genotyping in guiding treatment as well as preventive strategies.
Agenda
June 2, 2015
- 8:30 a.m.
- Welcome and Overview
Griffin Rodgers, Director, NIDDK
- 8:45 a.m.
- Keynote Address: When good proteins behave badly
Feroz Papa, UCSF
Function of ApoL1 – Cell Biology
Larry Holzman, Univ. of Penn. & Ora Weisz, Univ. of Pitts.
(15 min. talk, followed by 15 min. discussion)
- 9:30 a.m.
- Renal cell biology of ApoL1
Katalin Susztak, Univ. of Penn.
- 9:45 a.m.
- Q/A
- 10:00 a.m.
- Pathophysiology of ApoL1 kidney disease
Martin Pollak, Harvard Univ.
- 10:15 a.m.
- Q/A
- 10:30 a.m.
- Chloride channel activity of ApoL1
John C. Edwards, St. Louis Univ.
- 10:45 a.m.
- Q/A
- 11:00 a.m.
- Zebrafish models of ApoL1
Erica Davis, Duke Univ.
- 11:15 a.m.
- Q/A
- 11:30 a.m.
- Break
Function of ApoL1 – Lipoproteins
Rebekah Rasooly, NIDDK & Katalin Susztak, Univ. of Penn.
(15 min. talk, followed by 15 min. discussion)
- 11:45 a.m.
- Apolipoproteins, lipids and CVD
Dan Rader, Univ. of Penn.
- 12:00 p.m.
- Q/A
- 12:15 p.m.
- Apolipoproteins including ApoL1 and ALS
Teepu Siddique, Northwestern Univ.
- 12:30 p.m.
- Q/A
- 12:45 p.m.
- Teasing out function of disease proteins, using polycystin as an example
Stefan Somlo, Yale Univ.
- 1:00 p.m.
- Q/A
- 1:15 p.m.
- Lunch
Epidemiology and Genetic Epidemiology
John Sedor, Case Western Res. & Nancy Cox, Vanderbilt
(15 min. talk, followed by 15 min. discussion)
- 2:15 p.m.
- ApoL1 as risk factor for sickle cell nephropathy
Allison Ashley-Koch, Duke
- 2:30 p.m.
- Q/A
- 2:45 p.m.
- Genetic epidemiology of kidney disease in Sickle Cell Disease
Alex Reiner, Univ. of Washington
- 3:00 p.m.
- Q/A
- 3:15 p.m.
- Genetic epidemiology of ApoL1 kidney disease
Karl Skorecki, Technion, Israel
- 3:30 p.m.
- Q/A
- 3:45 p.m.
- Population genetics of ApoL1 risk alleles
Cherie Winkler, NCI
- 4:00 p.m.
- Q/A
- 4:15 p.m.
- Break
Translational research
Karl Skorecki, Technion & Stefan Somlo, Yale
(15 min. talk, followed by 15 min. discussion)
- 4:30 p.m.
- Screening for small molecule therapeutics in zebrafish
Randall Peterson
- 4:45 p.m.
- Q/A
- 5:00 p.m.
- Trypanosomes and host genetics
Annette MacLeod, Univ. of Glasgow
- 5:15 p.m.
- Q/A
- 7:00 p.m.
- Keynote: Balancing selection for disease alleles
Sarah Tishkoff, Univ. of Penn.
Introduced by Robert Star, NIDDK
- 7:45 p.m.
- Panel Discussion
Panelists - TBN
- 8:30 p.m.
- Poster session
June 3, 2015
- 8:30 a.m.
- Keynote Address: Ethical and policy issues related to using complex genetic information in treating complex disease
Lainie Friedman Ross, Univ. of Chicago
Introduced by Marva Moxey-Mims, NIDDK
ApoL1 – prevention and health disparities
TBD & Jeffrey Kopp, NIDDK
(15 min. talk, followed by 15 min. discussion)
- 9:15 a.m.
- Screening patients for ApoL1 risk alleles
Erwin Bottinger, Mt. Sinai School of Med.
- 9:30 a.m.
- Q/A
- 9:45 a.m.
- TBD
Charmaine Royal, Duke Univ.
- 10:00 a.m.
- Q/A
- 10:15 a.m.
- Health disparities and ApoL1 disease
Neil Powe, UCSF
- 10:30 a.m.
- Q/A
- 10:45 a.m.
- Break
Renal Transplantation and ApoL1
Paul Kimmel, NIDDK & Barbara Murphy, Mt. Sinai School of Med.
(15 min. talk, followed by 15 min. discussion)
- 11:00 a.m.
- Kidney Transplant Perspectives: HIV and other viruses, what we know and what we need to know
Dan Brennan, Wash. Univ.
- 11:15 a.m.
- Q/A
- 11:30 a.m.
- Polyoma virus
Dave Wang, Wash. Univ.
- 11:45 a.m.
- Q/A
- 12:00 p.m.
- ApoL1 and kidney transplantation
Barry Freedman, Wake Forest Univ.
- 12:15 p.m.
- Q/A
- 12:30 p.m.
- Viral coinfection: GB C virus and HIV
Jack Stapleton, Univ. Iowa
- 12:45 p.m.
- Q/A
- 1:00 p.m.
- Lunch
Risk factors
Barry Freedman, Wake Forest Univ. & Cherie Winkler, NCI
(15 min. talk, followed by 15 min. discussion)
- 2:00 p.m.
- Genetic modifiers of disease
Lindsay Farrer, Boston Univ.
- 2:15 p.m.
- Q/A
- 2:30 p.m.
- H3Africa and H3Kidney
Akinlolu Ojo, Univ. of Michigan
- 2:45 p.m.
- Q/A
- 3:00 p.m.
- HIVAN – a 30 year perspective
Michael Ross, Mt. Sinai School of Med.
- 3:15 p.m.
- Q/A
- 3:30 p.m.
- The way forward
Robert Star, Director, DKUHD, NIDDK
Discussants - TBN
